将基因检测嵌入转移性前列腺癌诊疗路径：患者与医生观点理解

数据集获取（Figshare）

• 源站标题：Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives
• DOI：10.6084/m9.figshare.30499902.v1
• 发布日期：2025-10-31
• 文件数：2 个
• 文件总体积：2.57 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Embedding_genetic_testing_in_the_metastatic_prostate_cancer_pathway_understanding_patient_and_physician_perspectives/30499902

命令行下载

curl -L -o "ifon_a_2577337_sm5068.pdf" "https://ndownloader.figshare.com/files/59204827"
curl -L -o "ifon_a_2577337_sm0028.pdf" "https://ndownloader.figshare.com/files/59204830"

文件清单

• ifon_a_2577337_sm5068.pdf（1.28 MB）
• ifon_a_2577337_sm0028.pdf（1.29 MB）

文件总体积 2.57 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

To understand how genetic (homologous recombination repair [HRR], including BReast CAncer [BRCA]) testing is being embedded in clinical practice and identify testing challenges given global approvals of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) for metastatic prostate cancer (mPCa).
Data from two Adelphi Real World Prostate Cancer Disease Specific Programmes™ (DSPs; 2020 and 11/2022–7/2023) were analyzed and compared using appropriate bivariate tests.
Genetic testing was performed among 45% (855/1899) of patients with mPCa (castration-sensitive [mCSPC]: 36%; castration-resistant [mCRPC]: 49%; HRR genes: 43% [34%; 47%]; BRCA: 42% [34%; 46%]). Testing increased from 2020: HRR genes by 17% (p BRCA by 18% (p BRCA mutations were reported in 16% (mCSPC: 13%; mCRPC: 18%) and 15% (13%; 16%) of patients, respectively. In the 2022–2023 DSP, 56% of physicians indicated they were more likely to conduct HRR gene testing following PARPi availability. Patient refusal, costs, reimbursement issues, low sample availability, and result delays were testing challenges. Among 40% of patients who spoke with physicians about testing, 83% were tested, and 49% reported knowing results helped.
Understanding physicians’ and patients’ experiences with, and challenges surrounding, genetic testing for PCa may facilitate better clinical-management interactions.
What is this article about?
Genetic testing for some genes (e.g., homologous recombination repair [HRR], including BReast CAncer [BRCA]) may help guide treatment of patients with metastatic prostate cancer (mPCa). Testing rates and results, and physicians’ and patients’ views of testing, were studied using data from real-world surveys conducted in 2020 and 11/2022–7/2023.
What were the results?
Almost half of patients with mPCa had genetic testing, about four in 10 had HRR gene or BRCA testing, and testing increased between surveys. Patients seeing medical oncologists were tested more often than patients seeing urologists. As per guideline recommendations, tested patients were younger, had worse disease, and were more likely to have a family history of cancer than non-tested patients. About four in 10 pati

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.30499902.v1（source: https://tandf.figshare.com/articles/dataset/Embedding_genetic_testing_in_the_metastatic_prostate_cancer_pathway_understanding_patient_and_physician_perspectives/30499902）。